Clinical Trial Detail

NCT ID NCT02553642
Title Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

melanoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Nivolumab

Ipilimumab

Age Groups: adult

No variant requirements are available.